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Summary Prophylactic antibiotics are commonly used for prevention of uri-
nary tract infections (UTIs) in children. It was postulated that the organisms and
resistance patterns of breakthrough infections would differ with the choice of
antimicrobial prophylaxis. This was a retrospective descriptive study of all break-
throughs UTI from 2000 to 2006 in children over 1 month of age discharged from
a referral children’s hospital in Tehran, Iran on continuous antibiotic prophylaxis
for UTIs. Fifty-seven children discharged on prophylaxis had breakthrough UTIs of
which 32 (56%) had a previously diagnosed urinary tract anomaly. Escherichia coli
was responsible for the majority of infections irrespective of choice of prophylaxis.
Thirty-three of 56 breakthrough UTIs (59%) were with organisms that were resistant
to the prophylactic antibiotic. There was an increased incidence of resistance to
prophylaxis in children on ceﬁxime (16 of 22; 78%) when compared with children on
cephalexin (7 of 19; 37%; p = 0.02) and a trend toward increased resistance when
compared with children on trimethoprim—sulfamethoxasole (3 of 8; 37%) (p = 0.10).
In conclusion, the resistance pattern of organisms causing breakthrough UTIs varies
with the choice of prophylaxis which should be taken into consideration in chosing
empiric therapy for such infections.
© 2009 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
∗ Corresponding author at: Room 8213, Aberhart Centre One, 11402 University Avenue, Edmonton, AB, Canada T6G 2J3.
Tel.: +1 780 407 3666; fax: +1 780 407 7136.
E-mail address: jr3@ualberta.ca (J.L. Robinson).
1876-0341/$ — see front matter © 2009 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.jiph.2009.08.002
i
a
b
n
w
i
c
w
R
t
c
o
t
o
e
l
e
t
p
a
p
t
b
f
m
i
b
4
O
T
p
p
E
T
m
R
D
B
a
b
s148
Introduction
Urinary tract infections (UTI) occur in 1—5% of chil-
dren with recurrences being common. A study of
134 females and 128 males with a UTI in the ﬁrst
year of life described a 35% recurrence rate in males
and 32% in females during the 3-year follow-up
period [1]. A signiﬁcant number of these UTIs result
in hospitalization. Local unpublished data showed
that of 1159 children hospitalized with a UTI March
2001 to March 2009, 66 children (5.7%) were subse-
quently readmitted with a recurrence. Continuous
prophylaxis with trimethoprim—sulfamethoxazole
(TMP—SMX), nitrofurantoin [2] or cephalosporins
[3—5] have been commonly used for children
who are prone to UTIs on the basis of voiding
dysfunction, obstructive uropathy, high grade vesi-
coureteral reﬂux (VUR), or infected renal stones
to prevent development of renal scars [6,7]. Of
late, there has been less enthusiasm for antibi-
otic prophylaxis, primarily because studies have
demonstrated questionable efﬁcacy in preventing
UTIs [7], especially for children with low grade VUR.
Nonetheless, prophylaxis is likely to continue to be
used for children who are very high-risk for recur-
rent pyelonephritis.
A major concern is the development of UTIs with
antibiotic-resistant ﬂora in children on prophylaxis.
The goal of this study was to analyze the resistance
pattern of UTI isolates from children on prophy-
laxis and correlate it with the choice of antibiotic,
with the hypothesis being that the antibiogram of
organisms from breakthrough infections would be
inﬂuenced by the choice of prophylaxis.
Methods
Design, setting, and participants
This was a retrospective descriptive cross-sectional
study of all breakthrough UTIs from January 1,
2000 to December 31, 2006 in Ali Asghar Children’s
Hospital—–a referral teaching hospital in Tehran,
Iran for children up to age 18 years. All patients over
1 month of age who had been discharged on antibi-
otic prophylaxis for UTIs and were subsequently
admitted up to December 31, 2006 with a break-
through UTI after being on antibiotic prophylaxis for
minimum 1 month were enrolled. The dose used for
prophylaxis was one-third of the therapeutic dose
of the antibiotic.Study protocol
Breakthrough infection was deﬁned as greater than
108 colony forming units per liter (105 colony form-
m
n
o
d
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ng units per milliliter) in a urine culture with an
bnormal urinalysis (deﬁned as greater than 5 white
lood cells per high-powered ﬁeld or a positive
itrite test or both) and a clinical course compatible
ith a UTI. Suprapubic urines are rarely obtained
n our center; this relatively high colony count was
hosen to ensure all patients had true UTIs. Patients
ith mixed growth in the urine were excluded.
esults of bagged urines were accepted only if
here were two specimens collected with identi-
al results. Data was collected on the presence
f urinary tract anomalies, most recent prophylac-
ic antibiotic, and the resistance pattern of the
rganism isolated from the urine. Children were
xcluded if it appeared compliance with prophy-
axis had been poor and were enrolled only once
ven if they had more than one breakthrough infec-
ion.
The standard method for processing urine sam-
les is that the sample is placed in a sterile dish
nd sent to the laboratory within 20min. It is then
lated on the blood agar medium for gram posi-
ive and the MacConkey’s agar for Gram-negative
acteria, and subsequently on Muller—Hinton agar
or antibiogram. Antibiotic discs (Padtan Teb CO.
ade by Iran) are used with antimicrobial sensitiv-
ty interpreted according to standard NCCLS criteria
y measuring the halo diameter of each disc after
8 h.
utcomes
he types of microorganisms and their resistance
atterns were correlated with the most recent pro-
hylactic antibiotic.
thical issues
his research was approved by the Research Com-
ittee of the Iran University of Medical Sciences.
esults
emographics
reakthrough infection associated with hospital
dmission was identiﬁed in 57 patients who had
een discharged with UTI as their ﬁnal diagno-
is, including 35 females and 22 males aged 1.9
onths to 18 years (mean 4.2 years). There were
o fungal breakthrough infections. The duration
f prophylaxis had been 1—2 months for 32 chil-
ren (56%), 3—6 months for 13 children (23%), 7—12
onths for 3 children (6%), 13—24 months for 1
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.ig. 1 Organisms causing breakthrough UTIs in 57 chil-
ren on antibiotic prophylaxis.
hild (2%), 25—36 months for 5 children (8%), and
ver 36 months for 3 children (5%). The indication
or prophylaxis was vesicoureteral reﬂux (N = 14;
5%), neurogenic bladder (N = 9; 16%), uretero-
elvic junction obstruction (N = 3; 5%), rectovesical
stula (N = 2; 4%), duplicated ureter (N = 2; 4%), pos-
erior urethral valves (N = 1; 2%), and dysplastic
idney (N = 1; 2%). The other 25 children (44%) had
diopathic recurrent UTIs, renal scars with no recog-
ized predisposing conditions, voiding dysfunction,
r were very young at the onset of their ﬁrst UTI.
orty children (70%) had no previous UTIs with pro-
hylaxis being started because of renal anomalies,
4 (24%) had one previous UTI and 3 (6%) had two
revious UTIs.
tiologic organisms causing breakthrough
TIs
tiologic organisms were Escherichia coli (N = 31;
4%), Staphylococcus saprophyticus (N = 10; 17.5%),
seudomonas species (N = 8; 14%), Enterobacter
pecies (N = 4; 7%), Klebsiella species (N = 3; 5%)
nd Proteus vulgaris (N = 1; 2%) with organisms
ppearing to vary by the choice of antibiotic for
rophylaxis (Fig. 1). Antibiotic prophylaxis in the
7 patients and their prophylactic agents were as
hown in Table 1 with the most common agents
eing ceﬁxime in 22 cases (39%) and cephalexin in
9 cases (33%). Escherichia coli was responsible for
he majority of the breakthrough UTIs irrespective
f choice of prophylaxis (Table 1). Thirty-three of
6 breakthrough UTIs (59%) were with organisms
hat were resistant to the prophylactic antibiotic
Table 1), with susceptibilities not being available
or one child on ciproﬂoxacin prophylaxis. There
as a trend towards patients on ceﬁxime being
ore likely to have breakthrough infections that
ere resistant to the prophylactic antibiotic than
ere children on TMP—SMX (p = 0.10). Children on T
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ceﬁxime were more likely to have isolates resis-
tant to their prophylaxis than were children on
cephalexin (p = 0.02). The number of children on
other antibiotics was too small to compare resis-
tance rates.
Table 2 demonstrates a high rate of resistance
to all commonly used antibiotics in isolates from
breakthrough urinary tract infections.
Discussion
This study showed that as expected, over half of
breakthrough UTIs in children discharged on antibi-
otic prophylaxis were with organisms resistant to
the antibiotic chosen for prophylaxis. However,
there was an increased incidence of resistance to
the prophylactic antibiotic in children prescribed
ceﬁxime when compared with children prescribed
cephalexin and a trend toward increased resis-
tance when compared with children prescribed
TMP—SMX. It is possible this ﬁnding is because com-
pliance was better with ceﬁxime, ensuring that UTIs
only occurred with resistant organism. However, it
is also possible that this result may indicate that
ceﬁxime is more likely than other choices of antibi-
otic to select for resistant bacteria in the bowel
ﬂora that then infect the urinary tract.
We are not aware of any previously published
data on choice of antibiotics or on resistance rates
in breakthrough infections in Iran. However, in the
neighboring country Turkey, a study showed increas-
ing resistance to ampicillin and TMP—SMX with a
trend towards increasing resistance to gentamicin
and ceftriaxone among isolates from breakthrough
infections in children who were taking chemo-
prophylaxis [8], but this study did not correlate
resistance rates with choice of prophylaxis.
Recent guidelines published by the National
Institute of Health and Clinical Excellence in the
United Kingdom recommend abandoning the rou-
tine prophylaxis of UTIs in children [9], in part
due to a signiﬁcant increase of antibiotic resistance
[10]. However, prophylaxis is likely to continue
to be used by many practitioners, especially for
children with frequent pyelonephritis. Choice of
antibiotic for prophylaxis is complex. In the cur-
rent study the isolates from breakthrough UTIs in
children taking TMP—SMX had low resistance rates
to the usual empiric UTI therapies (cephalosporins
and gentamicin) such that this agent might be still
a good candidate for prophylaxis in Iran. Further-
more, a recent study from Taiwan showed that
children on TMP—SMX as prophylaxis for VUR had a
lower risk of having breakthrough UTIs with multi- T
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esistant organisms, including extended-spectrum
eta-lactamase producing organisms as compared
ith children on cephalosporins. On the other hand,
he same study showed a lower UTI recurrence rate
or children on cephalosporins than for children
n TMP—SMX as prophylaxis [11]. In the Cochrane
eview, over half of children on ceﬁxime prophy-
axis had a possible adverse reaction to the drug
12] but it is not clear if this differs from other
ephalosporins or from other classes of antibiotics.
itrofurantoin is frequently prescribed for UTI pro-
hylaxis, but it does not cover Proteus species and
ts gastrointestinal side effects and hemolysis in
6PD deﬁciency (which has high prevalence in Iran)
estrict its use.
Choice of antibiotics for breakthrough infections
s equally complex and is markedly inﬂuenced by
ocal resistance patterns. The current study showed
high incidence of resistance to antibiotics that
ould be commonly chosen such a cefotaxime
65% resistance) and gentamicin (50% resistance).
owever, it is possible that organism such as S.
aprophyticus might be susceptible in vivo despite
esistance in vitro so these resistance rates may be
alsely high.
Over half the breakthrough UTIs occurred within
months of the prophylaxis being prescribed. It
s possible that in some cases this occurred as
he child was discharged on prophyalxis that their
riginal UTI organism was resistant to. However,
ince 70% of the children had no previous UTI, it
eems likely that resistance to prophylaxis some-
imes develops quickly.
This study had many limitations. Only children
dmitted to hospital with UTIs could be included,
iasing the results by including only children with
ore severe breakthrough infections. The diagnosis
f pyelonephritis (versus cystitis) was presumptive
n some cases. The doses of the prophylactic
ntibiotics were not recorded, although we think
ll children likely received standard dosing. We
ould not be certain all parents or patients were
ompliant with prophylaxis and the fact that 46%
f children had UTIs with organisms that were
usceptible to their prophylactic agent suggests
ompliance may have been sub-optimal, presum-
bly related to cost or taste of the drug, adverse
vents perceived by the parent to be drug-related,
nconvenience, or lack of belief that prophylaxis
as necessary. However, this makes the study more
epresentative of what happens in practice than is a
rospective study where compliance is monitored.
ome children might have received antibiotics
ther than their prophylactic drug for non-urinary
ract infections prior to being admitted with a
TI which might have altered the susceptibility151
attern of the urinary isolate. We did not have
usceptibility data on the isolates from the original
TI in the 30% of children with a previous UTI to
e certain the choice of prophylactic agent was
lways appropriate. The incidence of breakthrough
TIs with different types of prophylaxis could not
e calculated as we did not have data on the
ype of prophylaxis prescribed for the children
ischarged on prophylaxis who did not have break-
hrough UTIs. It is vital to note that results from
ran may not be applicable to other settings with
ifferent resistance patterns for uropathogens.
inally, there was not a control group to determine
he susceptibility pattern of organisms isolated
rom subsequent UTIs in children not on antibiotic
rophylaxis.
In conclusion, the resistance pattern of organ-
sms from breakthrough UTIs is related to the type
f antibiotic prophylaxis that has been prescribed.
hildren prescribed ceﬁxime as prophylaxis for UTIs
ay be more likely to develop UTIs with organ-
sms that are resistant to their prophylaxis than
re children prescribed other antibiotics including
ephalexin and possibly TMP/SMX. However, the
elative incidence of UTIs in children prescribed dif-
erent types of antibiotic prophylaxis is of prime
mportance and is yet to be established. The great-
st priority in the ﬁeld is to establish the efﬁcacy of
ntibiotic prophylaxis for UTIs in different settings.
hen, for settings where it appears to be indicated,
here should be large randomized trials of different
hoices of prophylaxis, collecting data on suscepti-
ilities of breakthrough infections, keeping in mind
hat the ideal choice of antibiotic will vary depend-
ng on the local resistance patterns.
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